Journal
ORAL ONCOLOGY
Volume 124, Issue -, Pages -Publisher
ELSEVIER
DOI: 10.1016/j.oraloncology.2021.105666
Keywords
-
Categories
Funding
- Pharmacodynamic Research Foundation
Ask authors/readers for more resources
Identifying predictive biomarkers of response and resistance to ICIs is necessary across various malignant tumors, as demonstrated by varying responses to nivolumab in different metastatic lesions within the same patient. Molecular analysis may aid in predicting the efficacy of ICI treatment and selecting appropriate therapeutic agents.
Patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M HNSCC) have a poor prognosis. Recently, the use of immune checkpoint inhibitors (ICIs) for drug treatment has been expanding . However, the response rate to immunotherapy is low. Therefore, the identification of predictive biomarkers of response and resistance to ICIs is required for various types of malignant tumors. We report the case of a patient with recurrent and metastatic HNSCC who simultaneously showed different responses to nivolumab in metastatic lesions. After administering nivolumab, metastasis to the multiple cervical lymph node metastases showed a significant reduction, whereas a new metastasis to the right axillary lymph node occurred . Each surgical specimen was analyzed using the cancer gene panel test (FoundationOne CDx) to elucidate why treatment response is distinct among the same patient. Next-generation sequencing revealed MYC amplification and programmed cell death-1 loss in the right axillary lymph nodes but not cervical lymph nodes. Furthermore, t he histopathological findings suggested that MYC amplification regulated programmed death-ligand 1 expression and was involved in a decreased response to ICIs. This result is expected to help predict the efficacy of ICI treatment and select therapeutic agents.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available